Peripherally Acting Mu-Opioid Receptor Antagonists (PAMORAs) for Opioid-Induced Constipation

Indications and Usage

The National Comprehensive Cancer Network recommends peripherally acting mu-opioid receptor antagonists for opioid-induced constipation when traditional laxatives have failed to provide adequate relief, with specific FDA-approved indications varying by agent and patient population 1
Methylnaltrexone is FDA-approved for opioid-induced constipation in adults with advanced illness receiving palliative care, according to the National Comprehensive Cancer Network 1, 2
Naloxegol is FDA-approved for opioid-induced constipation in adults with chronic noncancer pain, including those with chronic pain related to previous cancer or its treatment, as stated by the National Comprehensive Cancer Network 1
Naldemedine is FDA-approved for opioid-induced constipation in adults with chronic noncancer pain, including those with chronic pain related to prior cancer or treatment, and has the strongest recommendation with high-quality evidence for laxative-refractory opioid-induced constipation, according to Praxis Medical Insights 1, 3

Always rule out mechanical bowel obstruction or impaction before initiating PAMORAs, as recommended by the National Comprehensive Cancer Network and Gut 1, 2, 3
Assess for other causes of constipation, such as hypercalcemia, hypokalemia, hypothyroidism, and diabetes mellitus, as suggested by Praxis Medical Insights 3, 4
PAMORAs are indicated only after insufficient response to traditional laxatives, according to the National Comprehensive Cancer Network and Gut 1, 2, 5
First-line therapy should include stimulant laxatives with or without stool softeners, as recommended by the National Comprehensive Cancer Network and Praxis Medical Insights 1, 3
The goal is to achieve one non-forced bowel movement every 1-2 days, as stated by the National Comprehensive Cancer Network and Praxis Medical Insights 1, 3

Methylnaltrexone should be dosed at 0.15 mg/kg every other day subcutaneously, as recommended by Gut and Mayo Clinic Proceedings 2, 6
Naloxegol should be dosed at 25 mg once daily, with a reduced dose of 12.5 mg for moderate-to-severe renal impairment, as stated by Praxis Medical Insights 3
Naldemedine should be dosed at 0.2 mg once daily, with no dose adjustment needed for renal or mild-to-moderate hepatic impairment, as suggested by Praxis Medical Insights 3

All PAMORAs work by antagonizing peripheral mu-opioid receptors in the GI tract without crossing the blood-brain barrier, as explained by Gut and the National Comprehensive Cancer Network 1, 2
PAMORAs do not interfere with centrally-mediated opioid analgesia, according to the National Comprehensive Cancer Network and Gut 1, 2
Hold PAMORAs on the day of surgery but continue preoperatively, and monitor for opioid withdrawal symptoms, as recommended by Mayo Clinic Proceedings 6, 7

Never initiate PAMORAs without first ruling out bowel obstruction, as warned by the National Comprehensive Cancer Network and Praxis Medical Insights 1, 3
Do not use PAMORAs as first-line therapy, as they are indicated only after laxative failure, according to the National Comprehensive Cancer Network, Gut, and Praxis Medical Insights 1, 2, 3
Monitor for opioid withdrawal symptoms, particularly abdominal pain, diarrhea, and nausea, as suggested by Mayo Clinic Proceedings 6, 7

Peripherally acting μ‑opioid receptor antagonists (PAMORAs) block hydromorphone and other opioids from binding to μ‑opioid receptors in the gastrointestinal tract while preserving central analgesia. 8
PAMORAs antagonize μ‑opioid receptors in the enteric nervous system, directly preventing opioid‑induced constipation. 9

Naloxegol 25 mg orally once daily is supported by a strong recommendation with moderate‑quality evidence for treating laxative‑refractory opioid‑induced constipation. 8
Methylnaltrexone 0.15 mg/kg subcutaneously every other day receives a conditional recommendation with lower‑quality evidence, though some network meta‑analyses suggest possible superiority over other PAMORAs. 8

PAMORAs are indicated only after an inadequate response to traditional laxatives—including stimulant agents (e.g., senna, bisacodyl) and osmotic agents (e.g., polyethylene glycol, lactulose). 8